Lantern Pharma Inc. , a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, today announced ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

Cells process dynamic signaling inputs to regulate fate decisions during development. While oscillations or waves in key developmental pathways, such as Wnt, have been widely observed, the principles ...

This study presents a fundamental discovery of how cerebellar climbing fibers modulate plastic changes in the somatosensory cortex by identifying both the responsible cortical circuit and the ...

Hematopoietic reprogramming reflects the selective and evolutionarily conserved engagement of transcription factor networks that encode innate immune memory in long-lived stem cells.

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...

This valuable study investigates the role of HIF1a signaling in epicardial activation and neonatal heart regeneration in mice. Using a combination of genetic and pharmacological approaches, the ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...